---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-216844"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:23:02.278006+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience Q2 2022: FYARRO sales $3.4M, net loss $18.3M, cash $118.7M

## Summary
- FYARRO net product sales $3.4M for Q2 2022, first full quarter after launch.
- Net loss $18.3M (vs $1.5M in Q2 2021), includes $3.7M impairment charge.
- Cash and equivalents $118.7M; expected to fund operations into 2024.
- PRECISION 1 trial (TSC1/TSC2) enrollment ongoing; preliminary data expected 1H23.
- Permanent J-code (J9331) for FYARRO effective July 1, 2022 from CMS.

## SEC filing metadata
- accession: 0001193125-22-216844
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312522216844/0001193125-22-216844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312522216844/d349452d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-216844
- JSON: https://secwatch.observer/filing/0001193125-22-216844.json
- Plain text: https://secwatch.observer/filing/0001193125-22-216844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.